Novavax, Inc. NVAX

NAS: NVAX | ISIN: US6700024010 16/09/2026

9,350 USD (+1,30%)

(+1,30%) 16/09/2026

Grafiek Novavax, Inc.

Grafiek Novavax, Inc.

1 dag1d 1,30%
1 week1w 0,54%
1 maand1m 15,86%
3 maanden3m -1,58%
6 maanden6m -12,12%
1 jaar1j 11,44%
5 jaar5j -96,06%

Novavax, Inc. in het nieuws

Toon enkel gratis nieuws

2 september 2026 · Novavax to Participate in September Investor Conferences · Persbericht

28 augustus 2026 · Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season · Persbericht

6 augustus 2026 · Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights · Persbericht

30 juli 2026 · Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 · Persbericht

1 juni 2026 · Novavax to Participate in 2026 Jefferies Global Healthcare Conference · Persbericht

7 mei 2026 · Novavax to Participate in BofA Securities 2026 Health Care Conference · Persbericht

6 mei 2026 · Novavax Reports First Quarter 2026 Financial Results and Operational Highlights · Persbericht

29 april 2026 · Novavax to Report First Quarter 2026 Financial Results on May 6, 2026 · Persbericht

30 maart 2026 · Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development · Persbericht

26 februari 2026 · Novavax to Participate in Upcoming Investor Conferences · Persbericht

Profiel Novavax, Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.novavax.com

Hoofdzetel: Gaithersburg, Maryland Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe